{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:26:02Z","timestamp":1793622362613,"version":"4.5.0"},"reference-count":113,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"National Natural Science Foundation of China","award":["32571422"],"award-info":[{"award-number":["32571422"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,11,2]]},"DOI":"10.1080\/13543776.2026.2733162","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:05:41Z","timestamp":1789362341000},"page":"1011-1027","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Aurora kinase inhibitors: an updated patent review (2021\u2013present)"],"prefix":"10.1080","volume":"36","author":[{"given":"Yao-Sheng","family":"Zhang","sequence":"first","affiliation":[{"name":"Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-5559","authenticated-orcid":false,"given":"Junmin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wu","family":"Chen","sequence":"additional","affiliation":[{"name":"Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0473"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-026-02606-7"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1245"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90374-7"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000718"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107976"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.05.004"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2014.10.025"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.03.050"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.09.049"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02353-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00642-1"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00392-7"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.08.045"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21994"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.09.005"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00290"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2012.04.018"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-06-0208"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.628"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2022.55.2.169"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113371"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2008.04.013"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.03.013"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00899"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1178"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.084913"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26351"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33672-4"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543770802646949"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2011.574614"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.931374"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1890027"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1536"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0693-7"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70051-3"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0121-6"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1912"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac151"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1958"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4103"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.06.012"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04457-9"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2290"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7949"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04293-3"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800984v"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26324"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3012"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0469"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0529"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-01049-3"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35751"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901913s"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9798-6"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.196665"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01100-3"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13141"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02076-x"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA5504"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0012"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad338"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2979"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02185-2"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-026-03414-0"},{"key":"e_1_3_4_69_1","unstructured":"Meng X Ye Y Hu X et al.; Shanghai University of Medicine & Health Sciences. Preparation of quinoline derivatives with dual inhibitory effects on aurora kinase B and epidermal growth factor receptor as antitumor agent. CN120289432A. 2025."},{"key":"e_1_3_4_70_1","unstructured":"Yang Q Shan S Zhou Y et al.; Shenzhen Chipscreen Biosciences Co. Ltd. and Shenzhen Chipscreen Pharmaceutical Co. Ltd. Preparation of naphthamide compounds used as Aurora B kinase inhibitors. CN118255713A. 2024."},{"key":"e_1_3_4_71_1","unstructured":"Lu G Zhang B Zhu C et al.; Sun Yat-Sen University. Preparation of methyl pyrazolyl aminoquinazolinyl derivatives as Aurora kinase inhibitors for treatment\/prevention of proliferative diseases. CN115403568A. 2022."},{"key":"e_1_3_4_72_1","unstructured":"Lu G Chen S Zhang B et al. Preparation of quinazoline derivatives as aurora kinase inhibitor for treatment\/prevention of proliferative disease. CN118496207A. 2024."},{"key":"e_1_3_4_73_1","unstructured":"Wang DY Gao Y Zhou J et al.; Suzhou Acesola Pharmaceutical Co. Ltd. Novel quinazoline-containing compound and intermediate thereof and use thereof. WO2021115432A1. 2021."},{"key":"e_1_3_4_74_1","unstructured":"Xie Y Fan H Qian L et al. Preparation of pyridine based compounds as aurora kinase inhibitor and its application in preparation of anti-tumor drugs. WO2021110009A1. 2021."},{"key":"e_1_3_4_75_1","unstructured":"Xie Y Fan H; WIGEN Biomedicine Technology (Shanghai) Co. Ltd. Aurora kinase inhibitor and use thereof. WO2021008338A1. 2021."},{"key":"e_1_3_4_76_1","unstructured":"Cheng D Chen M Li A et al.; Jacobio Pharmaceuticals Co. Ltd. Novel heterocyclic compounds useful as aurora a selective inhibitors and their preparation. WO2021147974A1. 2021."},{"key":"e_1_3_4_77_1","unstructured":"Zhou M Zhang R He H et al.; Guizhou Medical University. Application of a compound in inhibiting activity of Aurora and jak kinase families and in treatment of several tumors. CN119499253A. 2025."},{"key":"e_1_3_4_78_1","unstructured":"Orton D Fei DL Saleh S et al.; StemSynergy Therapeutics Inc. Preparation of N-substituted cyclopropane-1 1-dicarboxamides as myc inhibitors and uses thereof. WO2021163192A1. 2021."},{"key":"e_1_3_4_79_1","unstructured":"Fang H Zhang Z Wu A et al.; WuXi AppTec (Shanghai) Co. Ltd. Preparation of s-triazine derivatives with Aurora kinase inhibition activity and its application in preparation of antitumor agents. CN116554169A. 2023."},{"key":"e_1_3_4_80_1","unstructured":"Niu C Xie B Shi M et al.; Xinjiang Technical Institute of Physics & Chemistry Chinese Academy of Sciences. Preparation of indolone derivatives and their applications. CN121005686A. 2025."},{"key":"e_1_3_4_81_1","unstructured":"Chung Y-H Han EH Min JY et al.; Korea Basic Science Institute. Pharmaceutical composition for preventing or treating cancer. WO2023113461A1. 2023."},{"key":"e_1_3_4_82_1","unstructured":"Chen S Zhang X Xiang R et al. Preparation of 4-amine substituted phthalazinone aurora kinase B inhibitor and preparation as anticancer agent. CN113773263A. 2021."},{"key":"e_1_3_4_83_1","unstructured":"Zhang G Cai J Xu X et al.; Yaokang Zhongtuo (Jiangsu) Pharmaceutical Technology Co. Ltd. Preparation of deuterated azaindole bipyrazole compounds as Aurora kinase inhibitor for cancer treatment. CN115572294A. 2023."},{"key":"e_1_3_4_84_1","unstructured":"Zhang G Cai J Xu X et al.; Yaokang Zhongtuo (Jiangsu) Pharmaceutical Technology Co. Ltd. Deuterated azaindole amino-pyrazole carboxamide compound and application thereof as protein kinase inhibitor for resisting tumor. CN115746002A. 2023."},{"key":"e_1_3_4_85_1","unstructured":"Ma T Fang L Shi F et al.; BioFront Ltd. Preparation of pyrrolo[2 3-b]pyridines as inhibitors of HPK1 FLT3 and Aurora a kinase for treating cancers. WO2023245329A1. 2023."},{"key":"e_1_3_4_86_1","unstructured":"Kurup SRK; Ferris State University. Substituted pyrrolo[2 3-d]pyrimidines and pyrazolo[3 4-d]pyrimidines as inhibitors for multi-resistant cancers. US11814388B1. 2023."},{"key":"e_1_3_4_87_1","unstructured":"Wagner B Reiner J Moschopoulou AA et al.; Eberhard Karls Universitaet Tuebingen. Preparation of imidazo[4 5-b]pyridin-7-amine compounds binding Aurora kinase a and uses thereof. WO2025196288A1. 2025."},{"key":"e_1_3_4_88_1","unstructured":"Reiner JJ Pantsar T Floetgen D et al.; Eberhard Karls Universitaet Tuebingen. Synthesis of Aurora kinase a protein-protein interaction modulators treating cancers. WO2022096679A1. 2022."},{"key":"e_1_3_4_89_1","unstructured":"Zheng Y Zhou S Men H et al.; Xuzhou Medical University. Preparation of pyrazole-imidazole-benzene compounds and its application. CN120040421A. 2025."},{"key":"e_1_3_4_90_1","unstructured":"Xiang H Hussein H Wang D et al.; Shandong Qianfoshan Hospital. Aurora kinase inhibitor and its application in the preparation of antitumor drugs. CN114276227A. 2022."},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-00652-y"},{"key":"e_1_3_4_92_1","unstructured":"Kong R Piao L Chang S et al.; Primary (Changzhou) Biotechnology Co. Ltd. Primary (Suzhou) Biotechnology Co. Ltd. and Suzhou Medinoah Co. Ltd. Preparation of quinazoline derivatives and their application as antitumor drugs. CN120943815A. 2025."},{"key":"e_1_3_4_93_1","unstructured":"Lu G Xu H Deng X et al.; Sun Yat-Sen University. Preparation of pyrrolopyrimidine compounds and their application. CN120441597A. 2025."},{"key":"e_1_3_4_94_1","unstructured":"Ma T Fang L Shi F et al.; BioFront Ltd. Preparation of pyrrolo[2 3-b]pyridines as degraders of HPK1 FLT3 MEK 1\/2 and Aurora a kinase for treating cancers. WO2023245327A1. 2023."},{"key":"e_1_3_4_95_1","unstructured":"Ding K Ma D Zhang Z et al.; Shanghai Institute of Organic Chemistry Chinese Academy of Sciences and Livzon Pharmaceutical Group Co. Ltd. Preparation of ((piperidylisoindolinylaminoalkoxyquinazolinyl) oxophenyl) quinolinecarboxamides as protein kinase degradation agent. WO2022253283A1. 2022."},{"key":"e_1_3_4_96_1","unstructured":"Ryu SH Kim SH Lee HK et al.; Uppthera Inc. Preparation of 2 4-dianilinopyrimidine-based Aurora-A kinase degradation-inducing compound. WO2026014945A1. 2026."},{"key":"e_1_3_4_97_1","unstructured":"Harki DA Tang J Hirsch LE et al. Preparation of therapeutic compounds to degrade Aurora kinase A and N-Myc and antitumor uses thereof. WO2026036043A1. 2026."},{"key":"e_1_3_4_98_1","unstructured":"Coker E Emery A Garnett M et al.; Genome Research Limited. BCL-2 inhibitors and aurora kinase inhibitors for treating cancer. WO2023152339A1. 2023."},{"key":"e_1_3_4_99_1","unstructured":"Wang R Zhou Q; Eastern General Hospital of People\u2019s Liberation Army. Application of Aurora-A kinase inhibitor combined with Donafenib in the preparation of drugs for treating hepatocellular carcinoma. CN119792283A. 2025."},{"key":"e_1_3_4_100_1","unstructured":"Ghosh S Johnson F; University of Texas System. Compositions and methods for the treatment of human papillomavirus-driven cancers. WO2024186883A2. 2024."},{"key":"e_1_3_4_101_1","unstructured":"Boulet SL Gong X Guo D et al.; Eli Lilly and Company. Preparation of substituted pyrazinobenzoxazepines and related compounds as kras G12c inhibitors and Aurora a inhibitors. WO2023196887A1. 2023."},{"key":"e_1_3_4_102_1","unstructured":"Qin W Jin H; Shanghai Cancer Institute. Application of lenvatinib and VIC-1911 in the preparation of cancer suppressing drugs. CN116509862A. 2023."},{"key":"e_1_3_4_103_1","unstructured":"Li A Hao W Zhang J et al.; JS Innopharm (Suzhou) Ltd. and Vitrac Therapeutics LLC. Combination of aurora a and PARP inhibitors for treatment of cancers. WO2024088193A1. 2024."},{"key":"e_1_3_4_104_1","unstructured":"Zhu S Xie Z Zhu J et al.; Qingdao University. Pharmaceutical composition for combined immunotherapy of breast cancer melanoma and\/or colorectal cancer and its application. CN115702930A. 2023."},{"key":"e_1_3_4_105_1","unstructured":"Guo Y Ni X Chang Y et al.; Beijing Children\u2019s Hospital Capital Medical University. Use of a combination of an Aurora a inhibitor and a LUBAC inhibitor in the manufacture of a medicament for the treatment of neuroblastoma. CN119909190A. 2025."},{"key":"e_1_3_4_106_1","unstructured":"Hapuarachchige S; The Johns Hopkins University. Delivery of Aurora kinase inhibitors using nano-scale drug delivery platforms by covalent conjugation. WO2025212557A1. 2025."},{"key":"e_1_3_4_107_1","unstructured":"Li H Yang G Long W et al.; Jacobio Pharmaceuticals Co. Ltd. Pyrazole derivatives and polymorphic forms as aurora a inhibitors and their preparation. WO2023005957A1. 2023."},{"key":"e_1_3_4_108_1","unstructured":"Kreiner M Halbert G Budhdeo S et al.; Ellipses Pharma Ltd. and Institute of Cancer ResearchRoyal Cancer Hospital (The). Pharmaceutical formulations comprising 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl) -2-(1 3-dimethyl -1-hpyrazol-4-yl)-3h-imidazo[4 5-b]pyridine. WO2021176214A1. 2021."},{"key":"e_1_3_4_109_1","unstructured":"Loughrey J Kelk N Kreiner M et al.; Ellipses Pharma Ltd. and Institute of Cancer Research Royal Cancer Hospital (The). Synthesis of imidazopyridine heterocyclic polymorphs and salts treating proliferative disorders with Aurora kinase and\/or FLT3 activity. WO2021176216A1. 2021."},{"key":"e_1_3_4_110_1","unstructured":"Xu C Xie L He M et al.; Beijing Tiantan Hospital Capital Medical University. Application of Aurora kinase B inhibitor in preparing medicament for treating brain stem glioma with good therapeutic effect. CN120459104A. 2025."},{"key":"e_1_3_4_111_1","unstructured":"Fan J Yang J Wen X et al.; Ninth People\u2019s Hospital Shanghai Jiaotong University School of Medicine. Aurora kinase a inhibitors for treating retinoblastoma in infants and young children. CN118236493A. 2024."},{"key":"e_1_3_4_112_1","unstructured":"Zhou Y Shan S Zhang X et al.; Shenzhen Chipscreen Biosciences Co. Ltd. and Chengdu Chipscreen Pharmaceutical Ltd. Pharmaceutical composition containing protein kinase inhibitor and medical use thereof. WO2022247844A1. 2022."},{"key":"e_1_3_4_113_1","unstructured":"Liang B Li T Yu Z et al.; Fuwai Hospital Chinese Academy of Medical Sciences Shenzhen People\u2019s Hospital and Xiangya Hospital Central South University. The application of Aurora kinase B inhibitors in preparing drugs for treating pulmonary arterial hypertension. CN119139310A. 2024"},{"key":"e_1_3_4_114_1","unstructured":"Zhao Y Liu Z; Eastern General Hospital of People\u2019s Liberation Army. Application of Aurora kinase B inhibitor in preparation of drugs for treating or preventing kidney damage caused by autoimmune disease. CN113304153A. 2021"},{"key":"e_1_3_4_115_1","unstructured":"Qiao A Zeng Y Zhang Z et al.; Guangdong Pharmaceutical University. Target discovery for Alzheimer\u2032s disease and drug research development application based on the target. CN121114429A. 2025"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2733162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2733162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2733162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:26:07Z","timestamp":1793618767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2733162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":113,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,2]]}},"alternative-id":["10.1080\/13543776.2026.2733162"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2733162","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}